Search

Your search keyword '"Kengni, Aurelie Minelle Ngueko"' showing total 3 results
Start Over Author "Kengni, Aurelie Minelle Ngueko"
3 results on '"Kengni, Aurelie Minelle Ngueko"'

1. Evaluation of Circulating and Archived HIV-1 Integrase Drug-Resistance Variants among Patients on Third-Line ART in Cameroon: Implications for Dolutegravir-Containing Regimens in Resource-Limited Settings

Author

Fokam, Joseph, primary, Ngoufack Jagni Semengue, Ezechiel, additional, Molimbou, Evariste, additional, Etame, Naomi-Karell, additional, Santoro, Maria Mercedes, additional, Takou, Désiré, additional, Mossiang, Leonella, additional, Meledie, Alain Patrice, additional, Chenwi, Collins Ambe, additional, Yagai, Bouba, additional, Nka, Alex Durand, additional, Dambaya, Beatrice, additional, Teto, Georges, additional, Ka’e, Aude Christelle, additional, Beloumou, Grâce Angong, additional, Ndjeyep, Sandrine Claire Djupsa, additional, Fainguem, Nadine, additional, Abba, Aissatou, additional, Kengni, Aurelie Minelle Ngueko, additional, Tchouaket, Michel Carlos Tommo, additional, Bouba, Nounouce Pamen, additional, Billong, Serge-Clotaire, additional, Djubgang, Rina, additional, Saounde, Edith Temgoua, additional, Sosso, Samuel Martin, additional, Kouanfack, Charles, additional, Bissek, Anne-Cecile Zoung-Kanyi, additional, Eben-Moussi, Emmanuel, additional, Colizzi, Vittorio, additional, Perno, Carlo-Federico, additional, Ceccherini-Silberstein, Francesca, additional, and Ndjolo, Alexis, additional

Published
2022
Full Text
View/download PDF

2. Dolutegravir-Based Regimen Ensures High Virological Success despite Prior Exposure to Efavirenz-Based First-LINE ART in Cameroon: An Evidence of a Successful Transition Model

Author

Semengue, Ezechiel Ngoufack Jagni, primary, Fokam, Joseph, additional, Etame, Naomi-Karell, additional, Molimbou, Evariste, additional, Chenwi, Collins Ambe, additional, Takou, Désiré, additional, Mossiang, Leonella, additional, Meledie, Alain P., additional, Yagai, Bouba, additional, Nka, Alex Durand, additional, Dambaya, Beatrice, additional, Teto, Georges, additional, Ka’e, Aude Christelle, additional, Beloumou, Grâce Angong, additional, Djupsa Ndjeyep, Sandrine Claire, additional, Abba, Aissatou, additional, Kengni, Aurelie Minelle Ngueko, additional, Tommo Tchouaket, Michel Carlos, additional, Bouba, Nounouce Pamen, additional, Billong, Serge-Clotaire, additional, Sosso, Samuel Martin, additional, Colizzi, Vittorio, additional, Perno, Carlo-Federico, additional, Kouanfack, Charles, additional, Zoung-Kanyi Bissek, Anne-Cecile, additional, Eben-Moussi, Emmanuel, additional, Santoro, Maria Mercedes, additional, Ceccherini-Silberstein, Francesca, additional, and Ndjolo, Alexis, additional

Published
2022
Full Text
View/download PDF

3. Dolutegravir-Based Regimen Ensures High Virological Success despite Prior Exposure to Efavirenz-Based First-LINE ART in Cameroon: An Evidence of a Successful Transition Model.

Author

Semengue, Ezechiel Ngoufack Jagni, Fokam, Joseph, Etame, Naomi-Karell, Molimbou, Evariste, Chenwi, Collins Ambe, Takou, Désiré, Mossiang, Leonella, Meledie, Alain P., Yagai, Bouba, Nka, Alex Durand, Dambaya, Beatrice, Teto, Georges, Ka'e, Aude Christelle, Beloumou, Grâce Angong, Djupsa Ndjeyep, Sandrine Claire, Abba, Aissatou, Kengni, Aurelie Minelle Ngueko, Tommo Tchouaket, Michel Carlos, Bouba, Nounouce Pamen, and Billong, Serge-Clotaire

Subjects
EFAVIRENZ, VIRAL load, TENOFOVIR, INTEGRASE inhibitors, LAMIVUDINE, ANTIRETROVIRAL agents, HIV
Abstract

To ensure optimal prescribing practices in the dolutegravir-era in Cameroon, we compared first-line virological response (VR) under tenofovir + lamivudine + dolutegravir (TLD) according to prior exposure to tenofovir + lamivudine + efavirenz (TLE). A facility-based survey was conducted among patients initiating antiretroviral therapy (ART) with TLD (I-TLD) versus those transitioning from TLE to TLD (T-TLD). HIV viral load was performed and unsuppressed participants (VL > 1000 copies/mL) had genotyping performed by Sanger sequencing. Of the 12,093 patients followed, 310 (mean-age: 41 ± 11 years; 52.26% female) complied with study criteria (171 I-TLD vs. 139 T-TLD). The median ART-duration was 14 (12–17) months among I-TLDs versus 28 (24.5–31) months among T-TLDs (15 (11–19) on TLE and 14 (9–15) on TLD), and 83.15% (148/178) were at WHO clinical stages I/II. The viral suppression rate (<1000 copies/mL) was 96.45%, with 97.08% among I-TLDs versus 95.68% among T-TLDs (p = 0.55). VR was similar in I-TLD versus T-TLD at <400 copies/mL (94.15% versus 94.42%) and age, gender, residence, ART-duration, and WHO stages were not associated with VR (p > 0.05). Genotyping was successful for 72.7% (8/11), with no major mutations to integrase inhibitors found. VR is optimal under first-line TLD after 14 months, even among TLE-exposed, thus confirming the effectiveness of transitioning from TLE to TLD in similar settings, supported by strong pharmacological potency and genetic barrier of dolutegravir. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results